Cargando…

1110. In Vivo Pharmacodynamics of Vancomycin Against Staphylococci in Young Infants

BACKGROUND: Coagulase-negative staphylococci are the predominant pathogen causing late onset sepsis in young infants, however, the pharmacodynamic target for vancomycin therapy is unknown. This study aimed to determine the pharmacodynamic target of vancomycin in young infants with staphylococcal inf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gwee, Amanda, Duffull, Stephen, Zhu, Derek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644379/ http://dx.doi.org/10.1093/ofid/ofab466.1304

Ejemplares similares

1110. A multicenter Evaluation of Outcomes Associated With Oral Vancomycin Dose in Patients With Clostridium difficile Infection
por: Bidell, Monique, et al.
Publicado: (2018)

1110. Very Late Onset Infections Amongst Long Term Survivors of Kidney Transplantation
por: Cheung, Harry, et al.
Publicado: (2020)

1110. Outcomes Following Implementation of a Urine Culture
por: Simpson, Timothy, et al.
Publicado: (2019)

1437. Short Versus Long-Course Intravenous Antibiotics for Young Infants with Urinary Tract Infection
por: Lawrence, Jolie, et al.
Publicado: (2021)

Protocol for a randomised controlled trial of continuous infusions of vancomycin to improve the attainment of target vancomycin levels in young infants: The VANC trial
por: Gwee, Amanda, et al.
Publicado: (2018)

1259. Activity of eravacycline against staphylococci isolated from periprosthetic joint infections
por: Zhuchenko, Georg, et al.
Publicado: (2020)

Alternatives to Fight Vancomycin-Resistant Staphylococci and Enterococci
por: Baëtz, Benjamin, et al.
Publicado: (2021)

Vancomycin and Oxacillin Co-Resistance of Commensal Staphylococci
por: Soyege, Ariyo Oludotun, et al.
Publicado: (2014)

1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury
por: Avedissian, Sean N, et al.
Publicado: (2019)

Tu1110: EXPRESSION OF EPITHELIAL PROTEASES PREDICTS SARS-COV-2 ENTRY IN HUMAN ENTEROIDS
por: Alvarado, David M., et al.
Publicado: (2022)

Abstract: 11.10 Gluteal Augmentation Techniques: A Comprehensive Literature Review
por: Oranges, Carlo M., et al.
Publicado: (2017)

251. Poor Outcomes in the Treatment of Coagulase-Negative Staphylococci Periprosthetic Joint Infections
por: Case, Ayden, et al.
Publicado: (2021)

Comparison of In Vivo Pharmacokinetics and Pharmacodynamics of Vancomycin Products Available in Korea
por: Kim, Hee Kyung, et al.
Publicado: (2020)

1264. Assessment of In Vivo Efficacy of CF-296 in addition to Vancomycin (VAN) and Daptomycin (DAP) against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model
por: Asempa, Tomefa E, et al.
Publicado: (2020)

In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci
por: El-Azizi, Mohamed, et al.
Publicado: (2005)

Tranexamic Acid in Combination With Vancomycin or Gentamicin Has a Synergistic Effect Against Staphylococci
por: Benjumea, Antonio, et al.
Publicado: (2022)

476 Heterogeneous Vancomycin-Intermediate Coagulase-Negative Staphylococci in Neonates: Does treatment with Linezolid improve outcomes?
por: Blanchard, Ana Chelène, et al.
Publicado: (2014)

1376. Oral Vancomycin as Secondary Prophylaxis Against Clostridioides difficile Infection in Pediatric Patients
por: Bao, Hongkai, et al.
Publicado: (2020)

1110. Age-related effects of dexmedetomidine, an alpha-2 agonist, on coronary vasoactivity and cardiac function in guinea-pig hearts
por: Hongo, M, et al.
Publicado: (2014)

713. Vancomycin Heteroresistance in Coagulase Negative Staphylococci (CoNS) Causing Central Line-Associated Bloodstream Infection (CLABSI) in Pediatric Patients with Leukemia
por: Dao, Tina, et al.
Publicado: (2018)

2007. Impact of Combining Rapid Diagnostics with an Interpretation Guide on Vancomycin Usage for Contaminant Blood Cultures Growing Coagulase-Negative Staphylococci (CoNS)
por: Wu, Simon, et al.
Publicado: (2019)

118. Optimizing the management of coagulase-negative staphylococci (CoNS) contaminants by reporting the species name
por: Stone, Tyler J, et al.
Publicado: (2020)

620. Pharmacokinetic-Pharmacodynamic Analysis of Oral Vancomycin and Gut Microbiome Changes in Healthy Volunteers: an Exploratory Study
por: Jo, Jinhee, et al.
Publicado: (2022)

227. Evaluation of Empiric Vancomycin Utilization at 72 Hours Post Admission: is De-escalation of Vancomycin Appropriate?
por: Naderi, Mandana, et al.
Publicado: (2020)

1108. Evaluation of Vancomycin Dosing in Adolescents
por: Weaver, Ashley I, et al.
Publicado: (2021)

800. Oral Vancomycin Prophylaxis Against Clostridioides difficile in Patients Admitted to a Tertiary Academic Medical Center
por: Kopelman, David B, et al.
Publicado: (2020)

Comparative In Vitro Activity of New Lipoglycopeptides and Vancomycin Against Ocular Staphylococci and Their Toxicity on the Human Corneal Epithelium
por: André, Camille, et al.
Publicado: (2023)

Runs 1110 1113, The effects of PF13 on the ISR background
por: Gamble, J
Publicado: (1980)

SG-APSIC1110: Project quality development of zero stock
por: Nimnaparoj, Tussanee
Publicado: (2023)

1102. Evaluation of Vancomycin Accumulation in Patients with Obesity
por: Assadoon, Maha, et al.
Publicado: (2021)

1103. Minocycline (MIN) Pharmacodynamics (PD) against Stenotrophomonas maltophilia (STM) in a Neutropenic Murine Thigh Infection Model
por: Fratoni, Andrew J, et al.
Publicado: (2021)

1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against Pseudomonas aeruginosa (PSA) in the In Vitro Pharmacodynamic Model
por: Chen, Iris H, et al.
Publicado: (2020)

1586. A Comparative Analysis of In Vitro Susceptibilities of Vancomycin-Resistant Enterococci Against Doxycycline, Minocycline, Tigecycline, Eravacycline and Omadacycline
por: Chua, Mary Francine P, et al.
Publicado: (2020)

P1110: EFFICACY AND SAFETY OF IMMUNOCHEMOTHERAPY IN TREATMENT OF FOLLICULAR NON-HODGKIN’S LYMPHOMA DURING COVID-19 PANDEMIC: A STUDY OF KROHEM, THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES
por: Galusic, D., et al.
Publicado: (2022)

P1110: REAL-WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US)
por: Shah, Bijal, et al.
Publicado: (2023)

1096. Evaluation of Vancomycin Pharmacokinetics in Intravenous Drug Users
por: Weihs, Sayo, et al.
Publicado: (2021)

881. Efficacy of Antibiotic Prophylaxis with Vancomycin in Cardiothoracic Surgery
por: Cooper, Margaret, et al.
Publicado: (2020)

1091. Validation of an Allometrically Scaled Body Weight Equation to Predict Vancomycin Clearance and Guide 24-Hour Vancomycin AUC Dosing in Obese Patients
por: Footer, Brent, et al.
Publicado: (2021)

691. Activity of TNP-2092 Against Biofilms Formed by Prosthetic Joint Infection-Associated Staphylococci
por: Fisher, Cody, et al.
Publicado: (2019)

Trend of vancomycin susceptibility of staphylococci at a level 1 trauma centre of India
por: Jain, Neetu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fdf0ltfr93hrnv3f9dqhd4netc